Weekly Digest – October 2025 Weekly Digest – October 2025 29 October 2025: Enhertu approved in Canada as the first and only HER2-directed therapy for patients with HR-positive HER2-low or HER2-ultralow metastatic breast cancer, following disease progression after one or […]
Weekly Digest – October 2025 Weekly Digest – October 2025 30 October 2025: Marketing approval obtained in China for Meiyouheng (Becotatug Vedotin injection) The NMPA has granted marketing approval in China for Becotatug Vedotin injection, an innovative EGFR-targeted ADC developed […]
Weekly Digest – October 2025 Weekly Digest – October 2025 28 October 2025: GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives orphan drug designation in the EU GSK’s B7-H3-targeted ADC, GSK5764227 (GSK’227), has received Orphan Drug Designation (ODD) from the European Medicines […]
Weekly Digest – October 2025 Weekly Digest – October 2025 28 October 2025: Alphamab Oncology announces biparatopic HER2-targeting ADC JSKN003 was granted fast track designation by FDA for the treatment of PROC Alphamab Oncology’s biparatopic HER2-targeting ADC, JSKN003, has received […]
Weekly Digest – October 2025 Weekly Digest – October 2025 27 October 2025: Cellectar Biosciences receives rare pediatric disease designation from U.S. FDA for Iopofosine I 131 in relapsed or refractory pediatric high-grade glioma Cellectar Biosciences received Rare Pediatric Disease […]
Weekly Digest – October 2025 Weekly Digest – October 2025 27 October 2025: GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer GSK secured exclusive global rights from Syndivia to develop and commercialize a preclinical antibody-drug […]
